SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of the Earliest Event Reported: May 5, 2003
Date of Report: May 5, 2003
ICN Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
| | 1-11397
| | 33-0628076
|
(State or other jurisdiction of incorporation or organization) | | (Commission file number) | | (I.R.S. Employer Identification No.) |
3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip code)
(714) 545-0100
(Registrant’s telephone
number, including area code)
Item 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit No.
| | Description
|
|
99.1 | | Press Release dated May 5, 2003 |
Item 9. Regulation FD Disclosure.
The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Conditions.”
On May 5, 2003, ICN Pharmaceuticals, Inc. issued a press release announcing its first fiscal quarter results ended March 31, 2003 and will hold a conference call on such date. The press release is attached as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, ICN Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 5, 2003 | | | | | | ICN PHARMACEUTICALS, INC. |
|
| | | | | | | | | /s/ Robert W. O’Leary
|
| | | | | | | | | Chairman and Chief Executive Officer |
